Cardiogen

What is Cardiogen?

Cardiogen is a synthetic short peptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, positioned in the catalog as the myocardial / heart-muscle tissue-specific entry. It is most commonly cited as a tripeptide with the sequence Ala-Glu-Asp (AED), paralleling the naming convention of other Khavinson tissue-targeted short peptides (Vesugen / KED for vasculature, Livagen / KEDA for liver and immune, Cortagen / AEDP for cortex). The underlying claim is that Cardiogen selectively interacts with cardiac tissue and modulates gene expression patterns in aging cardiomyocytes, with proposed applications in age-related cardiac function decline, post-infarct recovery, and heart-muscle regeneration. The PubMed-indexed evidence specific to Cardiogen is small — only a handful of Khavinson-group or Russian-collaborator studies in rodent myocardial and tumor-modifying models — and independent Western replication is essentially absent. Reliable confirmation of the exact amino acid sequence in peer-reviewed literature is limited; the AED attribution comes primarily from Khavinson-aligned sources and commercial product listings rather than from a definitive published structural paper, which is itself part of the honest caveat on this peptide.

What Cardiogen Is Investigated For

Cardiogen is studied within the Khavinson bioregulator framework as the heart-tissue counterpart to the other organ-specific short peptides (Livagen for liver, Vesugen for vasculature, Cortagen for cortex) and is discussed for age-related cardiac function decline, post-infarct recovery, and cardiomyocyte support. The available peer-reviewed Cardiogen-specific evidence is small and concentrated in Russian-language or Russian-authored journals: an organotypic tissue-culture study showing Cardiogen stimulated cell proliferation in myocardial explants from old rats more strongly than in young rats, and a tumor-modifying study in senescent rats bearing M-1 sarcoma, plus the broader tissue-specificity literature that groups Cardiogen with other Khavinson short peptides. There are no PubMed-indexed randomized controlled trials in humans for any cardiovascular indication, no independent Western preclinical replication of the myocardial-regeneration claim, and no characterized human pharmacokinetics. Vendor and forum claims around post-infarct recovery, heart failure, or cardiac regeneration in humans significantly exceed what that evidence base can independently support. Cardiogen is sold as a research chemical or as a Russian-market dietary peptide complex (Peptides.ru / Khavinson Peptides line) depending on the channel, and has no FDA approval, no EMA approval, and no formal registration as a Western prescription medicine.

History & Discovery

Cardiogen is one of the organ-specific short peptide entries in the Khavinson bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. The program's methodology, laid out across decades of Russian-language publications and a smaller set of English-language reviews, was to take tissue-specific complex extracts from animal organs (thymus, pineal, liver, prostate, heart, etc.), fractionate them to identify putatively active short-peptide components, and then synthesize chemically defined short peptides claimed to reproduce the tissue-targeting effect. Cardiogen occupies the myocardial slot in this catalog — sometimes described as the synthesized counterpart of the older natural-extract preparation derived from cattle heart tissue — and is most commonly identified as the tripeptide Ala-Glu-Asp (AED), paralleling the short-sequence naming convention used for its sibling peptides. The PubMed-indexed literature on Cardiogen specifically is modest compared to flagship Khavinson entries like Epithalon or Thymalin: a handful of organotypic tissue-culture studies, a senescent-rat tumor-modifying study, and inclusion in broader tissue-specificity reviews. Independent Western preclinical replication by cardiology or structural-biology laboratories has not materialized, and there is no PubMed-indexed human clinical trial for Cardiogen in any cardiovascular indication. The peptide reaches Western users almost exclusively through research-chemical lyophilized vials labeled 'not for human use' or through the Russian-market Khavinson Peptides / Peptides.ru oral capsule line marketed as a dietary peptide complex — neither of which represents validated therapeutic use, and neither of which is regulated to the evidence standard that would normally accompany a drug for a cardiovascular indication.

How It Works

Cardiogen is proposed to act as a 'tissue-specific' short peptide that selectively interacts with heart-muscle cells and nudges their gene expression toward a healthier, younger pattern. The idea is that as the heart ages, genes involved in cardiomyocyte maintenance and repair become progressively silenced; a short peptide with the right sequence is claimed to bind DNA regulatory regions and reactivate some of those programs, supporting cell proliferation and survival in aged myocardium. This is the same general framework the Khavinson program applies to all its tissue-targeted short peptides — the specific details for cardiac tissue are much less established than for the better-studied members of the catalog.

Within the Khavinson bioregulator framework, Cardiogen (Ala-Glu-Asp) is proposed to act through direct interaction with DNA regulatory regions and histone proteins in cardiomyocytes, modulating chromatin accessibility and gene expression patterns in aging heart tissue. In an organotypic tissue-culture study (Chalisova et al., Adv Gerontol 2009), Cardiogen stimulated cell proliferation in myocardial explants from old rats substantially more than in explants from young animals, a pattern the Khavinson group interprets as evidence of age-dependent reactivation of silenced gene programs. The broader tissue-specificity literature (Zakutskii et al., Adv Gerontol 2006) groups Cardiogen with Livagen, Vesugen, Cortagen, and others, claiming each short peptide preferentially activates cells of its named target tissue through sequence-specific DNA recognition — though a concrete molecular mechanism for how a tripeptide achieves tissue-specific gene regulation has not been established even within the Khavinson literature and has not been independently validated by Western structural biology or chromatin research. A senescent-rat tumor-modifying study (Levdik and Knyazkin, Bull Exp Biol Med 2009) reported Cardiogen modified M-1 sarcoma growth dynamics in old animals, which is presented as evidence of age-dependent activity but is hard to interpret mechanistically — the direction of tumor-modifying effects is context-sensitive and is one of the safety signals that argues for caution rather than a straightforward therapeutic claim. Human cardiomyocyte data, structural data on the proposed DNA binding, and any formal receptor or binding-partner characterization are absent.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cardiogen:

• 01Definitive structural confirmation of the Cardiogen sequence — the AED (Ala-Glu-Asp) attribution comes primarily from Khavinson-aligned sources and commercial product listings rather than a single unambiguous peer-reviewed structural paper assigning that sequence to a molecule labeled 'Cardiogen.'
• 02Independent Western preclinical replication of the age-dependent myocardial proliferation finding by a cardiology or structural-biology laboratory operating outside the Khavinson research orbit, without which the entire single-research-orbit pattern remains unresolved.
• 03Any randomized controlled trial in humans, in any cardiovascular indication, at any dose, by any route — the complete absence of human controlled data is the single largest gap and the one that most directly limits what can honestly be said about the peptide.
• 04Human pharmacokinetic characterization — absorption (especially from the Russian-market oral capsule product), distribution, whether the intact tripeptide reaches cardiac tissue in any meaningful concentration after oral or subcutaneous administration, metabolism, and elimination kinetics are all unknown.
• 05A concrete molecular mechanism for the claimed tissue specificity — how a tripeptide is supposed to recognize myocardial DNA regulatory regions selectively over those in other tissues has not been worked out structurally or functionally even within the Khavinson literature, let alone independently.
• 06Characterization of the tumor-modifying signal reported in senescent rats — direction, dose-dependence, tumor-type dependence, and whether it generalizes beyond the M-1 sarcoma model — given that this is one of the only Cardiogen-specific findings outside the explicit cardiac context.
• 07Long-term safety data in animals with structural heart disease (post-infarct, hypertrophic, or failing myocardium), since extrapolating from healthy-rodent proliferation data to diseased human hearts is exactly the inferential leap the existing evidence cannot support.
• 08Honest head-to-head comparison data against standard cardiology pharmacotherapy — not because any such comparison is realistic in the near term, but because in its absence the implicit framing of Cardiogen as a cardiovascular intervention substantially overstates its position.

Forms & Administration

Cardiogen reaches users through two primary channels: Russian-market oral capsules sold as dietary peptide complexes (Peptides.ru / Khavinson Peptides brand line), and Western research-chemical injectable lyophilized powder labeled 'not for human use.' Russian protocols describe short courses (10–30 days) of daily oral capsules repeated periodically. Research-chemical injectable protocols, where used, follow the subcutaneous convention of other Khavinson short peptides at roughly 100–200 mcg per dose, reconstituted in bacteriostatic water. No Western clinician operates a validated Cardiogen protocol. All peptides should only be used under the guidance of a qualified healthcare provider — and for any cardiovascular condition, standard cardiology care is dramatically better evidenced than Cardiogen. Never self-administer without clinician oversight.

Common Questions

Who Cardiogen Is NOT For

Drug & Supplement Interactions

There are no formally characterized drug interactions for Cardiogen because there are no human pharmacokinetic studies, no human clinical trials, and no interaction studies of any kind. All discussion of drug interactions is therefore theoretical and should be treated as such. The most relevant practical concern is not a pharmacokinetic interaction in the conventional sense but a clinical-care displacement risk: if a user with cardiovascular disease leans on Cardiogen instead of titrating their actual cardiology regimen (beta-blockers, ACE inhibitors or ARBs, statins, antiplatelet therapy, anticoagulants where indicated, diuretics in heart failure), the resulting under-treatment of the underlying condition is a far more concrete threat than any direct molecular interaction. If a tripeptide bioregulator did genuinely modulate cardiomyocyte gene expression as claimed, theoretical concerns would include unintended effects on cardiac conduction in patients on antiarrhythmics, potential interactions with electrophysiologically active drugs, and unpredictable effects on remodeling in patients on heart-failure pharmacotherapy — none of which have been studied. Coadministration with any cardiovascular prescription medicine should be treated as uncharacterized; cardiology pharmacotherapy should never be paused, reduced, or skipped to accommodate Cardiogen use, and any such decision belongs with the prescribing cardiologist, not with a peptide forum.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions